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ABSTRACT
Background. Management of patients with clinically
detectable lymph node metastasis to the groin is by ilio-
inguinal or combined superficial and deep groin dissection
(CGD) according to most literature, but in practice super-
ficial groin dissection (SGD) only is still performed in
some centers. The aim of this study is to evaluate the
experience in CGD versus SGD patients in our center.
Methods. Between 1991 and 2009, 121 therapeutic CGD
and 48 SGD were performed in 169 melanoma patients
with palpable groin metastases at our institute. Median
follow-up was 20 and, for survivors, 45 months.
Results. In this heterogeneous group of patients, overall
(OS) and disease-free survival, local control rates, and
morbidity rates were not significantly different between
CGD and SGD patients. However, CGD patients had a
trend towards more chronic lymphedema. Superficial
lymph node ratio, the number of positive superficial lymph
nodes, and the presence of deep nodes were prognostic
factors for survival. CGD patients with involved deep
lymph nodes (24.8%) had estimated 5-year OS of 12%
compared with 40% with no involved deep lymph nodes
(p = 0.001). Preoperative computed tomography (CT)
scan had high negative predictive value of 91% for
detection of pelvic nodal involvement.
Conclusions. This study demonstrated that survival and
local control do not differ for patients with palpable groin
metastases treated by CGD or SGD. Patients without
pathological iliac nodes on CT might safely undergo SGD,
while CGD might be reserved for patients with multiple
positive nodes on SGD and/or positive deep nodes on CT
scan.
Management of patients with clinically detectable
lymph node metastasis to the groin consists of ilioinguinal
or combined superficial and deep groin dissection (CGD)
according to most literature.1–7 Some surgeons are willing
to do so only when there are multiple positive nodes in the
groin or when there is evidence of pelvic nodal involve-
ment on the basis of imaging information.8 In practice, a
solely inguinal or superficial groin dissection (SGD) is still
performed in some cases and/or centers. The potential
survival or local control benefit of extensive surgery
remains controversial in the absence of randomized data.
Prognosis and outcome of patients after CGD are
believed to correlate with the biology of the disease rather
than with the extent of the operation.4,8–11 It is advocated
that CGD should be performed when there is clinically
gross involvement of the groin, when there are clinically
detectable deep lymph nodes, when Cloquet’s node is
histologically positive or when pelvic computed tomogra-
phy (CT) demonstrates pelvic lymphadenopathy.12
The aim of this study is to evaluate the experience in
patients with clinically evident metastatic melanoma to the
groin who underwent CGD versus SGD only. Postoperative
morbidity, regional recurrence, preoperative CT scan,
and disease-free and overall survival were analyzed.
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The necessity of removal of the deep iliac and obturator
lymph nodes as well as prognostic factors for survival in
patients with metastatic melanoma to the groin were
evaluated.
PATIENTS AND METHODS
Patients
Patients in this study presented with clinically detectable
metastases to the groin at the Erasmus University Medical
Center – Daniel den Hoed Cancer Center, Rotterdam, The
Netherlands. Patients were selected for therapeutic ilioin-
guinal or combined superficial and deep groin dissection
(CGD) or for inguinal or superficial groin dissection
(SGD). All patients underwent the operation within
2 months of detection of palpable metastasis. Patients who
underwent sentinel lymph node biopsy were excluded. All
patient characteristics, tumor characteristics, postoperative
morbidities, regional recurrence patterns, and imaging
procedures (preoperative CT scan) were collected and
sorted in a database for this retrospective single-institution
study. Postoperative morbidities were collected from
patient charts and divided into two categories; short-term
morbidities, e.g., wound infection or necrosis, and seroma,
and long-term morbidities, e.g., chronic lymphedema.
Chronic lymphedema was recorded if moderate or severe
swelling was present for more than 6 weeks postopera-
tively and the patient required therapy. Adjuvant
radiotherapy was given to 16 (9.5%) patients, who were
treated with doses between 15 and 80 Gy.
Surgical Procedure
Four coauthors performed the majority of lymph node
dissections assessed for this study (J.H. de W., A.N. van G.,
A.M.M.E., and C.V.). In general, patients with palpable
inguinal nodes underwent CGD. Indication for SGD was
based on surgeon or patient preference. Patients with sig-
nificant (cardiopulmonary) comorbidities and absence of
preoperative radiological and/or clinical suspicion for
involved deep lymph nodes underwent SGD. SGD was
performed via a transverse inguinal incision and involved
complete dissection of lymph nodes from the inguinofe-
moral content to the apex of the femoral triangle where the
long saphenous vein joins the femoral vein. Sartorius
muscle transposition to cover and protect femoral vessels
was selectively performed when adjuvant radiotherapy was
to be expected and/or skin was at risk. When CGD was
performed, an additional incision was made approximately
3–5 cm above the line of the inguinal ligament. CGD
included dissection of the inguinofemoral and external iliac
nodes up to the common iliac artery (if necessary up to the
aortic bifurcation) and dissection of the obturator nodes.
Statistics
Disease-free survival (DFS) was calculated from oper-
ation date of lymph node dissection to date of first
recurrence at any site. Overall survival (OS) was calculated
from operation date of lymph node dissection to date of
death due to any cause.
Different statistical methods were applied as appropriate.
The chi-square test, Fisher’s exact test, and Mann–Whitney
test were applied to investigate differences in clinicopath-
ological features, the predictive value of the number of
involved superficial nodes for deep lymph node involve-
ment, postoperative morbidities, and regional recurrence
patterns in CGD and SGD patients. The log-rank test and
the Kaplan–Meier method were assessed for survival
analysis and the search for prognostic factors in CGD
patients, SGD patients, and the total group of patients. All
calculations were performed using STATA version 10.1
and 11.1 (StataCorp LP, College Station, TX, USA).
RESULTS
CGD Versus SGD
This study included 121 patients (70 women and 51
men) who underwent therapeutic combined superficial and
deep dissection (CGD) and 48 patients (32 women and 16
men) who underwent therapeutic superficial dissection
(SGD) for palpable melanoma metastases to the groin.
Surgeries were performed between 1991 and 2009 at the
Erasmus University Medical Center – Daniel den Hoed
Cancer Center, Rotterdam, The Netherlands. Median fol-
low-up time was 20 months for all patients and 45 months
for all survivors (both, range 1–202 months). Median age
at time of surgery was 54 (range 21–87) years. CGD
patients had significantly more patients with large super-
ficial nodes than SGD patients (p = 0.002), more harvested
superficial lymph nodes (p \ 0.001), and lower superficial
lymph node ratio (p = 0.0004) (Table 1).
Preoperative Diagnosis
Patients were clinically diagnosed by computed
tomography (CT), fine-needle aspiration cytology (FNAC),
and/or ultrasound. All SGD patients were diagnosed with
superficial lymph node involvement only. Of all CGD
patients, 24 (19.8%) were diagnosed with superficial and
deep lymph node involvement and 97 (80.2%) were diag-
nosed with only superficial lymph node involvement.
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TABLE 1 Clinicopathological
factors
IQR interquartile range
a p-Values calculated with the
Fisher exact test, chi-square test,
and Mann–Whitney test
Combined deep and
superficial groin
dissections
(n = 121), n (%)
Superficial groin
dissections
(n = 48), n (%)
p-Valuea
Gender
Female 70 (57.9) 32 (66.7) 0.303
Male 51 (42.2) 16 (33.3)
Age (years)
B50 47 (38.8) 11 (22.9) 0.072
[50 74 (61.2) 37 (77.1)
Site of primary
Leg 78 (78.8) 37 (92.5) 0.080
Trunk 21 (21.2) 3 (7.5)
Missing 22 8
Breslow thickness (mm)
B2.00 52 (57.1) 14 (38.9) 0.099
2.01– B 4.00 23 (25.3) 10 (27.8)
[4.00 16 (17.6) 12 (33.3)
Missing 30 12
Clark level
II–III 26 (32.1) 9 (30) 0.907
IV 48 (59.3) 19 (63.3)
V 7 (8.6) 2 (6.7)
Missing 40 18
Ulceration
Absent 89 (73.6) 34 (70.8) 0.706
Present 32 (26.5) 14 (29.2)
Extranodal invasion
Absent 33 (48.5) 14 (51.9) 0.823
Present 35 (51.5) 13 (48.2)
Missing 53 21
Largest diameter of positive superficial node (cm)
\3 21 (29.2) 11 (50.0) 0.002
C3 51 (70.8) 11 (50.0)
Missing 50 26
No. positive superficial nodes
1 57 (47.1) 26 (54.2) 0.553
2–3 35 (28.9) 14 (29.2)
[3 29 (24.0) 8 (16.7)
No. harvested superficial nodes, median (IQR) 15 (12–22) 8 (5–14) \0.001
Superficial lymph node ratio (%)
Median (IQR) 11 (6–25) 20 (10–50) 0.0004
B10 54 (45.4) 12 (25.0) 0.035
10– B 25 37 (31.1) 18 (37.5)
[25 28 (23.5) 18 (37.5)
Missing 2 0
Positive deep lymph nodes
Absent 91 (75.2) 48 (100.0) –
Present 30 (24.8) 0 (0.0)
Adjuvant radiotherapy 11 (9.1) 5 (10.4) 0.776
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Preoperative CT scans could be retrieved in 61 of 121
CGD patients. Of the 61 radiographically evaluated CGD
patients, 44 (62.1%) were diagnosed with only superficial
lymph node involvement, of which 40 were histologically
confirmed by the pathologist (negative predictive value for
pelvic involvement 91%). Positive predictive value for
pelvic metastases was 59%, sensitivity was 71%, and
specificity was 85% (Table 2).
Postoperative Morbidity
Median hospital stay was 6 (range 3–27) days in patients
with CGD and 6 (range 2–32) days in patients with SGD.
There were no statistically significant differences in post-
operative morbidities between CGD and CGD patients (all
p [ 0.05), although there was a trend towards more chronic
lymphedema in the CGD group (25.6% versus 14.6%,
p = 0.154) (Table 3).
Recurrence
There was no statistical difference in disease-free sur-
vival time or time to regional relapse between SGD and
CGD patients, with overall recurrence rate of 73% (90/121)
and 74% (35/48), respectively. At time of last follow-up,
81 of 121 patients (67%) in the CGD group and 31 of 48
patients (65%) in the SGD group were dead. Regional
recurrence rates were more common in SGD than in CGD
patients, i.e., 21% and 16% (p = 0.498), and pelvic
recurrence rates were 10% in both groups of patients
(p = 1.000). Median time to first recurrence was 7.6 (range
1–96) months for CGD patients and 6.0 (range 1–42)
months for SGD patients (p = 0.677) (Table 3).
Survival Analysis
Disease-free (DFS) and overall survival (OS) in CGD
patients were not better than in SGD patients (p = 0.722
and p = 0.647, respectively) (Fig. 1c, d). Comparison of
DFS and OS of CGD patients who only had superficial
nodes involved with SGD patients also showed no signif-
icant difference (p = 0.421 and p = 0.217, respectively).
Five-year estimated DFS and OS rates for patients who
underwent SGD were 15.7% and 28.7%, respectively.
Five-year estimated DFS and OS rates for patients who
underwent CGD were 18.3% and 33.0%, respectively
(Fig. 1c, d).
On univariate analysis of prognostic factors in the total
number of patients (n = 169), the number of positive
superficial nodes (1, 2–3, C4) was a significant prognostic
factor for DFS [C4 nodes only; hazard ratio (HR) = 1.85;
95% confidence interval (CI) 1.21–2.84; p = 0.005] and
OS (HR = 1.60; 95% CI 1.03–2.51; p = 0.038 and
TABLE 2 CT accuracy for pelvic lymph node involvement in CGD
patients
CT pelvic ? CT pelvic - Total
Histology pelvic ? 10 4 14
Histology pelvic - 7 40 47
Total 17 44 61
Sensitivity = 10/14 = 71.4%
Specificity = 40/47 = 85.1%
Positive predictive value = 10/17 = 58.8%
Negative predictive value = 40/44 = 90.9%
CT computed tomography, CGD combined deep and superficial groin
dissection
TABLE 3 Postoperative morbidity and regional recurrence rates
Type of morbidity Combined deep and superficial
groin dissections (n = 121), n (%)
Superficial groin
dissections (n = 48), n (%)
p-Valuea
Overall 77 (63.6) 24 (50.0) 0.119
Short termb 60 (49.6) 19 (39.6) 0.305
Long termc 32 (26.5) 8 (16.7) 0.229
Wound infection and/or necrosis 30 (24.8) 13 (27.1) 0.845
Chronic lymphedema 31 (25.6) 7 (14.6) 0.154
Type of recurrence
Median time to recurrence (months) 7.6 6.0 0.677
Regional superficial and deep lymph node recurrence 19 (15.7) 10 (20.8) 0.498
Of which: Pelvic lymph node recurrence 12 (9.9) 5 (10.4) 1.000
a p-Values calculated with the Mann–Whitney test, Fisher’s exact test, and chi-square test
b Short-term morbidities include wound infection and/or necrosis, seroma, postoperative bleeding, urinary tract infection, pulmonary embolism
or thrombosis, and transient nerve damage
c Long-term morbidities include chronic lymphedema, urinary tract damage, permanent nerve damage, and loss of function
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HR = 2.36; 95% CI 1.50–3.71; p = 0.0005) as well as
superficial lymph node ratio for DFS (HR = 2.33; 95% CI
1.25–4.34; p = 0.008) and OS (HR = 3.16; 95% CI
1.68–5.94; p \ 0.001). Presence of involved deep lymph
nodes was a prognostic factor for OS (HR = 1.95; 95% CI
1.24–3.07; p = 0.004).
On univariate analysis of prognostic factors in SGD
patients only, the largest diameter of the positive lymph
node was significant for OS (HR = 3.10; 95% CI
1.07–8.98; p = 0.037), while analysis in CGD patients
revealed superficial lymph node ratio, more than three
positive superficial nodes, as well as presence of involved
deep lymph nodes as poor prognostic factors for OS
(HR = 5.90, 95% CI 2.21–15.76, p \ 0.001; HR = 2.29,
95% CI 1.34–3.91, p = 0.002; and HR = 2.25, 95% CI
1.38–3.66, p = 0.001, respectively) and DFS (HR = 4.64,
95% CI 1.70–12.65, p = 0.003; HR = 1.96, 95% CI
1.19–3.22, p = 0.008; and HR = 1.61, 95% CI 1.02–2.55,
p = 0.041, respectively) (Table 4).
Five-year estimated DFS and OS rates for positive deep
lymph nodes were 9.1% and 12.5%, respectively, com-
pared with 5-year estimated DFS and OS rates for positive
superficial lymph nodes only in CGD patients of 21.5% and
39.7% (Fig. 1a). Five-year estimated DFS rates for the
number of positive superficial lymph nodes was 23.7% for
1, 12.0% for 2–3, and 11.2% for C4 involved nodes. Five-
year estimated OS rates for the number of positive super-
ficial lymph nodes was 42.6% for 1, 25.8% for 2–3, and
17.1% for C4 involved nodes (Fig. 1b).
DISCUSSION
Survival in patients with palpable metastatic melanoma
to the groin is poor. In the literature, estimated 5-year
overall survival (OS) rates vary from 20% to 40%.8,11,13 In
our series of 169 patients with palpable nodes in the groin,
5-year estimated OS rates were 33% for CGD and 29% for
SGD. Also 5-year DFS rates were virtually identical, i.e.,
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FIG. 1 Overall survival by (a) positive deep lymph nodes in CGD patients, (b) number of positive superficial nodes in all patients, and (c) type
of groin dissection. d Disease-free survival by type of groin dissection
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18% for CGD and 16% for SGD. Patients with CGD with
positive deep nodes have the poorest prognosis, with OS
ranging from 6% to 34% in the literature.7,8,10,14–16
(Table 5). In our institute, patients with CGD and positive
deep nodes have estimated 5-year OS and DFS rates of 12%
and 9%. In contrast, for CGD patients without deep nodal
involvement, we observed 40% and 22%, respectively.
There were differences between the CGD and SGD
patients. CGD patients had a significantly larger size of
involved superficial lymph nodes than SGD patients
(Table 1). Moreover, 25% of CGD patients had involved
deep lymph nodes, while there was no suspicion and no
diagnosis of deep nodal involvement in SGD patients.
CGD patients had unfavorable preoperative prognosis,
which is apparent since selection for extent of surgery
was based on comorbidities and the suspicion of
involvement of deep lymph nodes. However, during
CGD, more superficial nodes were harvested and the
number of positive superficial nodes was not different,
resulting in a significant lower superficial lymph node
ratio (Table 1). Lower superficial lymph node ratio is a
good prognostic factor for survival.17–19 Based on surgery
only, CGD patients were expected to have favorable
prognosis. In this study, the outcome of CGD patients was
virtually identical to that of SGD patients (Fig. 1c, d).
Even comparison of patients with superficial involved
nodes only showed no difference, indicating that the
extent of groin surgery does not influence outcome (data
not shown; p = 0.217). Also in other studies, it has been
demonstrated that extent of groin surgery, regardless of
presence or absence of deep lymph node involvement in
CGD patients, has no effect on survival.8,10,16
TABLE 4 Cox regression univariate analysis of overall and disease-free survival for prognostic factors in CGD and SGD patients, and the total
group of patients
Combined deep and superficial groin dissections
(n = 121)
Superficial groin dissections
(n = 48)
All dissections (n = 169)
Disease-free survivala
HR 95% CI p HR 95% CI p HR 95% CI p
Largest diameter of superficial node (cm)
\3 1 1 1
C3 1.69 0.90–3.17 0.100 2.48 0.91–6.80 0.077 1.82 1.08–3.07 0.024
No. of positive superficial nodes
1 1 1 1
2–3 1.53 0.93–2.51 0.092 1.29 0.63–2.66 0.494 1.40 0.93–2.11 0.103
C4 1.96 1.19–3.22 0.008 1.85 0.77–4.41 0.167 1.85 1.21–2.84 0.005
Superficial lymph node ratio 4.64 1.70–12.65 0.003 1.64 0.66–4.08 0.283 2.33 1.25–4.34 0.008
Positive deep nodes
Absent 1 1
Present 1.61 1.02–2.55 0.041 N/Ab 1.48 0.96–2.28 0.075
Overall survivala
Largest diameter of superficial node (cm)
\3 1 1 1
C3 1.43 0.74–2.77 0.292 3.10 1.07–8.98 0.037 1.72 0.99–3.00 0.055
No. of positive superficial nodes
1 1 1 1
2–3 1.66 0.96–2.87 0.071 1.48 0.69–3.17 0.316 1.60 1.03–2.51 0.038
C4 2.29 1.34–3.91 0.002 2.44 0.99–6.01 0.052 2.36 1.50–3.71 0.0005
Superficial lymph node ratio 5.90 2.21–15.76 \0.001 2.27 0.88–5.88 0.091 3.16 1.68–5.94 \0.001
Positive deep nodes
Absent 1 1
Present 2.25 1.38–3.66 0.001 N/Ab 1.95 1.24–3.07 0.004
N/A not applicable, CGD combined deep and superficial groin dissection, SGD superficial groin dissections
a The following variables did not have any prognostic significance in all groups: gender, age, site of primary, Breslow thickness, Clark level,
ulceration, and extranodal invasion
b Variable not assessable due to no presence of positive deep nodes
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Preoperative CT was performed in 61 of 121 patients
who underwent CGD. Positive predictive value (PPV) of
CT scan was only 59% in our experience, whilst the neg-
ative predictive value (NPV) was fairly good at 91%.
Sensitivity was 71% and specificity 85% in our group of
patients (Table 2). Allen et al. found different results with
PPV of 100%, NPV of 86%, specificity of 100%, and
sensitivity of 60%, stating that CT scan was not reliable as
a tool for preoperatively assessing pelvic lymph node
involvement.4 However, both studies show that a CT-based
decision on whether or not to perform CGD could be
correctly made in 9 out of 10 patients. Thus, CT scan may
be used as a tool in the decision on whether or not to
remove deep lymph nodes.
Morbidity rates in the present study are divided into
short- and long-term morbidities. Underestimation of
events in the morbidity data could have occurred due to the
retrospective gathering of data from medical records.
However, comparison of the two groups of patients in this
study remains valid since this presumed underestimation
arose in both groups. Neither short- nor long-term mor-
bidities were significantly lower in SGD than in CGD
patients, being 39.6% versus 49.6% (p = 0.305) and 16.7%
versus 26.5% (p = 0.229), respectively (Table 3). The
most debilitating morbidity is chronic lymphedema,
which is difficult to define. Some authors have used
measurements to define this, whilst others have opted to
define chronic lymphedema as edema requiring interven-
tion. Also debated is the minimum period of edema to
define it as chronic, which we did when moderate or severe
swelling was present (more than) 6 weeks after surgery and
required treatment. In any case, it is a widely feared and
unpleasant complication.20–22 There was a trend towards
increased chronic lymphedema in patients after CGD
(25.6%) than in patients after SGD (14.6%), yet this dif-
ference was not statistically significant (p = 0.154). This
difference was not the result of an imbalance of additional
radiotherapy to the groin, as 10% of SGD patients received
radiotherapy versus 9% of CGD patients (p = 0.776). The
assessment of one large or two small incisions for CGD has
no influence on the rate of lymphedema as well.23 Other
reports also indicate that lymphedema rates after CGD
(range 23–55%) are greater than after SGD (range 7–29%),
albeit not always statistically significantly so.8,11,20,22 Far-
ies et al. recently reported the difference in lymphedema
rates between immediate and delayed lymph node dissec-
tion. In these data of the Multicenter Selective
Lymphadenectomy Trial (MSLT) I, lymphedema rates for
SGD patients were 21.4% when undergoing immediate
dissection and 22.6% when undergoing delayed dissection
(p = 0.9), while CGD patients had higher lymphedema
rates of 36.4% for immediate dissection and 34.2% for
TABLE 5 Overview of literature describing survival rates in patients with positive deep nodes to the groin diagnosed after therapeutic
combined deep and superficial lymph node dissection only
Institute Reference Year Study period Median
follow-up
(months)
No. of patients with
positive pelvic nodes
(% of total)
5-Year OS (%)
NCI/ALH Jonka, 27 1999 1961–1995 18 71 (20) 24
Strobbe7
UCLA Finck14 1982 1970–1980 23 24 (29) 17
MSKCC Coit10 1989 1974–1984 86b 10 (7) 6
Mann8 1999 1985–1994 40 21 (19) ±35
RPCI Karakousisc, 2,3,15,28 1996 1977–1993 ±46 48 (NR) 34
UE Meyer13 2002 1978–1997 20 23 (31) 21
MLUHW Kretschmer16 2001 1983–1994 68b 24 (35) 6
RMH Hughes11 2000 1984–1998 19 29 (40) 19
MDACC Badgwell29 2007 1990–2001 90 55 (51)d 42d
DDHCC Recent study 2011 1991–2009 20 30 (25) 12
OS overall survival; NR not reported; NCI/ALH Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands;
UCLA University of California, Los Angeles, CA; MSKCC Memorial Sloan–Kettering Cancer Center, New York, NY; RPCI Roswell Park
Cancer Institute, Buffalo, NY; UE University of Erlangen, Erlangen, Germany; MLU HW Martin-Luther-Universitat Halle-Wittenberg, Halle,
Germany; RMH Melanoma and Sarcoma Unit, Royal Marsden Hospital, London, UK; MDACC M.D. Anderson Cancer Center, Houston, TX;
DDHCC Erasmus Medical Center - Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
a The 23 patients (5-year overall survival 32%) reported by Jonk et al. in 1989 are included in the study performed by Strobbe et al
b The median survival shown is for patients who survived only. Median follow-up for the entire group is not reported
c The patients described in the three earlier reports (1986 and two reports in 1994) of Karakousis et al. are included in the 1996 study
d The patients in this study underwent any type of lymph node dissection and not only therapeutic lymph node dissections
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delayed dissection (p = 0.89).22 Unfortunately, p-values
for the difference in lymphedema between SGD and CGD
patients were not provided.22
Regarding locoregional control in the ilioinguinal
region, we found no differences between CGD and SGD, as
regional recurrence rates were similar (Table 3). The fre-
quency of pelvic recurrences was equal in both groups.
Possible causes for this counterintuitive observation could
be the small sample size, patient selection, i.e., SGD
patients having occult pelvic disease at time of surgery,
and/or the overall worse prognosis of both groups of
patients compared with literature. Patients might die of
distant visceral metastases before pelvic recurrence has
developed. Our results are in line with other reports in the
literature. Coit et al. reported similar nodal recurrence rates
for SGD and CGD patients, while Singletary et al. reported
relatively more nodal recurrence in SGD patients, but
attributed that to the extent of tumor burden rather than the
extent of surgery. 10,24
Our group of patients has worse survival compared with
literature; for example, Balch et al. reported 5-year OS
rates of 50% for N1b, 45% for N2b, and 40% for N3
patients in the 2009 AJCC melanoma staging system
analysis.25 Patients from our center showed (in the same
order) 5-year OS rates of 43%, 26%, and 17%. Because of
our relatively small study population compared with the
enormous AJCC databases of [ 30,000 patients, a single
event will have a greater impact on the estimate survival
rates in Kaplan–Meier analysis, because the number at risk
is smaller. Due to our relatively short median follow-up,
we underestimate our long-term survival. Moreover, all
patients were operated at the Erasmus University Medical
Center – Daniel den Hoed Cancer Center, a tertiary center
in The Netherlands for such cases. This implies that a
negative selection bias is most likely. More advanced cases
might lead to worse survival.
As well as the superficial lymph node ratio, the number
of positive superficial nodes was a consistent prognostic
variable for OS and DFS (Table 4). This is consistent with
the outcome after analysis of stage III melanoma patients
by the AJCC.25,26 With an increasing number of positive
superficial lymph nodes, the chance of involvement of the
deep lymph nodes increased. No patients with 1 involved
superficial node showed additional positivity in the pelvic
area, while this applied to 32% of patients with 2–3
involved superficial lymph nodes and to 66% of patients
with C4 involved superficial lymph nodes. A decision on
the extent of surgery might be made based on the number
of involved superficial lymph nodes. A scenario based on
our results of preoperative CT scan and the number of
involved superficial lymph nodes could be considered.
When preoperative CT is negative for involvement in the
pelvic region and only one superficial lymph node is
involved, SGD might be performed. When, after patho-
logical analyses of the SGD specimen, more than one
involved superficial lymph node is found, additional dis-
section of the pelvic region could be considered. CGD is
performed in case of suspicion of multiple positive super-
ficial lymph nodes and/or positive deep lymph nodes.
We acknowledge that this study is retrospective and has
short follow-up time. We selected patients who underwent
only therapeutic groin dissection for palpable disease and
excluded patients who underwent elective lymph node
dissection or sentinel node biopsy. The consequence was
that our clean cohort of melanoma patients underwent
surgery in a period of time (1991–2009) with evolving
practice and imaging. Before applying this scenario in
clinical practice, results similar to those of the present
study should be reported by other retrospective studies or a
randomized controlled trial.
In conclusion, the poor outcome in melanoma patients
with palpable nodal disease in the groin after CGD was
equal after SGD in our series and in many other reports in
the literature. Patients without overt iliac nodes on CT
might safely undergo SGD and be spared the greater
morbidity of CGD. CGD might be reserved for patients
with multiple positive nodes in the SGD and/or positive
nodes on CT scan. A prospective randomized controlled
trial is the only study that could overcome the classical
drawbacks of this and other retrospective studies.
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